NASDAQ : TELO
Telomir Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.9352 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 68.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 3.12M | 8.10M | 10.01M | 2.37M | 20.94K | 11.64K |
| Research & Development | 2.97M | 2.44M | 2.24M | 1.57M | 833.21K | 126.49K |
| Operating Expenses | 6.09M | 10.54M | 12.24M | 3.94M | 854.15K | 138.13K |
| Operating Income | -6.09M | -10.54M | -12.24M | -3.94M | -854.15K | -138.13K |
| Interest Expense | -2.90K | -4.34M | -1.64M | |||
| Interest & Investment Income | 214.10K | 125.64K | 48.00K | |||
| EBT Excluding Unusual Items | -5.88M | -10.41M | -16.53M | -5.59M | -854.15K | -138.13K |
| Other Unusual Items | -7.49M | |||||
| Pretax Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Net Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Net Income to Common | -51.99M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Shares Outstanding (Basic) | 40.36M | 31.65M | 29.54M | 27.30M | 26.83M | |
| Shares Outstanding (Diluted) | 40.36M | 31.65M | 29.54M | 27.30M | 26.83M | |
| EPS (Basic) | -1.29 | -0.33 | -0.56 | -0.48 | -0.03 | |
| EPS (Diluted) | -1.29 | -0.33 | -0.56 | -0.48 | -0.03 | |
| EBIT | -6.09M | -10.54M | -12.24M | -3.94M | -854.15K | -138.13K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 5.17M | 7.29M | 1.27M | 1.23K | 1.42K | |
| Cash & Short-Term Investments | 5.17M | 7.29M | 1.27M | 1.23K | 1.42K | |
| Prepaid Expenses | 195.62K | 54.69K | 57.87K | 713.00 | ||
| Other Current Assets | 433.28K | 47.31K | ||||
| Total Current Assets | 5.37M | 7.34M | 1.32M | 435.23K | 48.73K | |
| Long-Term Deferred Charges | 4.34M | |||||
| Total Assets | 5.37M | 7.34M | 1.32M | 4.77M | 48.73K | |
| Accounts Payable | 195.53K | 536.77K | 587.54K | 707.19K | 404.22K | 18.73K |
| Accrued Expenses | 417.47K | |||||
| Short-Term Debt | 136.90K | 473.75K | 93.43K | 628.38K | 581.79K | 119.40K |
| Total Current Liabilities | 332.42K | 1.43M | 680.97K | 1.34M | 986.01K | 138.13K |
| Total Liabilities | 332.42K | 1.43M | 680.97K | 1.34M | 986.01K | 138.13K |
| Additional Paid-In Capital | 48.76M | 46.92M | 31.24M | 17.50M | 55.00K | 55.00K |
| Retained Earnings | -43.72M | -41.01M | -30.60M | -14.06M | -992.28K | -138.13K |
| Comprehensive Income & Other | -55.00K | |||||
| Shareholders' Equity | 5.03M | 5.91M | 643.04K | 3.44M | -937.28K | -138.13K |
| Total Liabilities & Equity | 5.37M | 7.34M | 1.32M | 4.77M | 48.73K | |
| Total Debt | 136.90K | 473.75K | 93.43K | 628.38K | 581.79K | 119.40K |
| Net Cash (Debt) | 5.03M | 6.81M | 1.17M | -627.15K | -580.37K | -119.40K |
| Net Cash Per Share | 0.12 | 0.22 | 0.04 | -0.02 | -0.02 | |
| Filing Date Shares Outstanding | 68.77M | 34.38M | 29.76M | 29.61M | 27.10M | |
| Total Common Shares Outstanding | 68.77M | 34.38M | 29.76M | 28.61M | 26.83M | |
| Working Capital | 5.03M | 5.91M | 643.04K | -900.34K | -937.28K | -138.13K |
| Book Value Per Share | 0.07 | 0.17 | 0.02 | 0.12 | -0.03 | |
| Tangible Book Value | 5.03M | 5.91M | 643.04K | 3.44M | -937.28K | -138.13K |
| Tangible Book Value Per Share | 0.07 | 0.17 | 0.02 | 0.12 | -0.03 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Other Amortization | 4.34M | 1.61M | ||||
| Stock-Based Compensation | 916.47K | 6.13M | 6.87M | |||
| Other Operating Activities | 7.49M | |||||
| Change in Accounts Payable | -59.43K | -50.77K | 183.63K | 114.56K | 385.49K | 18.73K |
| Change in Other Net Operating Assets | 104.47K | 645.46K | -57.16K | -713.00 | ||
| Operating Cash Flow | -4.91M | -3.69M | -5.07M | -3.86M | -468.66K | -119.40K |
| Short-Term Debt Issued | 155.52K | 3.12M | 462.39K | 119.40K | ||
| Total Debt Issued | 380.31K | 155.52K | 3.12M | 462.39K | 119.40K | |
| Short-Term Debt Repaid | -101.00K | |||||
| Total Debt Repaid | -243.93K | -101.00K | ||||
| Net Debt Issued (Repaid) | 136.37K | 155.52K | -101.00K | 3.12M | 462.39K | 119.40K |
| Issuance of Common Stock | 8.51M | 9.55M | 6.87M | 1.00M | 55.00K | |
| Other Financing Activities | 682.29K | -433.94K | -255.97K | -47.31K | ||
| Financing Cash Flow | 9.33M | 9.71M | 6.34M | 3.86M | 470.08K | 119.40K |
| Net Cash Flow | 4.42M | 6.02M | 1.26M | -188.00 | 1.42K | |
| Levered Free Cash Flow | -3.07M | -86.57K | 1.10M | -1.96M | ||
| Unlevered Free Cash Flow | -3.07M | -86.57K | -527.61K | -2.55M | ||
| Change in Working Capital | 45.04K | 594.69K | 126.47K | 113.84K | 385.49K | 18.73K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 68.72M | 45.73M | 122.58M | |||
| Enterprise Value | 63.68M | 38.49M | 121.84M | |||
| Last Close Price | 0.92 | 1.33 | 4.12 | |||
| PB Ratio | 12.50 | 7.73 | 190.63 | |||
| P/TBV Ratio | 13.38 | 7.73 | 190.63 | |||
| Debt / Equity Ratio | 0.03 | 0.08 | 0.14 | 0.18 | -0.62 | -0.86 |
| Net Debt / Equity Ratio | -1.00 | -1.15 | -1.82 | 0.18 | -0.62 | -0.86 |
| Quick Ratio | 15.55 | 5.10 | 1.86 | 0.00 | 0.00 | |
| Current Ratio | 16.14 | 5.14 | 1.94 | 0.33 | 0.05 | |
| Return on Equity (ROE) | -213.10% | -317.65% | -810.18% | -1,045.36% | ||
| Return on Assets (ROA) | -122.81% | -152.03% | -250.96% | -102.18% | ||
| Return on Capital Employed (ROCE) | -120.90% | -178.20% | -1,903.80% | -114.70% | 91.10% | 100.00% |
| Earnings Yield | -138.00% | -22.77% | -13.49% | |||
| Buyback Yield / Dilution | -34.76% | -7.16% | -8.18% | -1.77% |